Articles On Immutep (ASX:IMM)

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

ShareCafeThe Week that Was – December 13-17, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do s...

Immutep (IMM) signs a manufacturing service agreement with Northway Biotech to manufacture its preclinical candidate for autoimmune diseases ahead of clinical testing Northway has already begun developing a manufacturing process for the dr...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...

The Immutep Ltd (ASX: IMM) share price is rising today after news of a deal with a European company. Shares in Immutep were swapping hands at 47.5 cents in early morning trade, up 1.06%. Let’s take a look at what may be influencing the Im...

Immunotherapy development company Immutep (ASX:IMM) has signed a Manufacturing Service Agreement with Northway Biotech.

ShareCafeLatest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook Immutep (ASX: IMM) are global leaders in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface mol...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The Immutep Ltd (ASX: IMM) share price is in the red this morning, down 1.05% at the time of writing to 47 cents. The biotech company is developing LAG-3 related immunotherapy treatments for patients with cancer and autoimmune disease. Bel...

Immutep (IMM) has treated the first five patients in its study evaluating eftilagimod alpha (efti) in conjunction with standard of care chemotherapy  No additional safety signs were observed during the study, which is the first time a trip...

Wall Street falls further on Omicron fears The US stock markets once again fell heavily overnight, as the US confirmed its first case of the omicron variant. Cases of omicron in South Africa have doubled in two days, with the new strain als...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study Patients are now participating across three p...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is up by 0.30%. Immutep Limited (ASX:IMM) has has successfully completed patient recruitment for the Phase II TACTI-002 study of LAG-3...

Tech stocks gain on Wall Street US stocks were mixed overnight, but investors’ appetite were mainly focused on the tech sector. The Dow Jones retreated 0.17% , but the S&P 500 was up 0.34%, and tech heavy Nasdaq by 0.45%. Megatech stock...

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

Wall Street was lower for the week US stocks rebounded on Friday, but finished the week lower after an inflation data-triggered selloff on Wednesday. All three US stocks benchmarks rose, led by tech – the Dow Jones by 0.5%, the S&P 500...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The AGM sea...

Despite what Immutep’s two-day sell-off may have you thinking, now is the time the biotech giants are going to do due diligence on Marc Voigt’s LAG-3 bet.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is trading lower. At the time of writing, the benchmark index is down 0.1% to 7,425.7 points. Four ASX shares that are falling more than most...

Shares in Australian biotechnology company Immutep Ltd (ASX: IMM) are tanking on Wednesday morning, down 20% to 56 cents. Immutep shares are on the move this morning after the company announced data from a Phase IIb trial on its lead drug...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

The Immutep Ltd (ASX: IMM) share price is climbing today after the biotechnology company announced it has secured a new patent. At the time of writing, Immutep shares are edging 1.7% higher to 59.5 cents. In the last month, its shares have...

Immutep (IMM) is granted a new patent by the Chinese Patent Office for its lead product candidate, eftilagimod alpha The new patent relates to methods of use of efti in combination with a chemotherapy agent to treat cancer The new Chinese...

Shares in Immutep (IMM) open green after the company announced positive feedback from European regulators around its lead anti-cancer drug candidate Immutep says the European Medicines Agency (EMA) supported IMM’s continued development of...

Nasdaq at all time high Tech stocks rallied in New York overnight, pushing up the Nasdaq composite index by 1.39% to its highest level ever. The Dow Jones rose by 0.68% and S&P 500 by 0.98% (also at all-time highs), capping off a good d...

Shares in clinical stage biotechnology company Immutep Ltd (ASX: IMM) are inching higher in afternoon trading, up 2.5% to 62 cents apiece. Immutep’s share price has been on the move amid the release of its annual report today, in which...

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

ShareCafeThe Week that Was – October 11-16, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafeImmutep Taking the Fight to Cancer In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). So impressed was he with IMM that Corporate Connect felt...

Global stocks sell off as bond yields rise All three US stock market benchmark indexes fell sharply overnight, as the 10-year benchmark US Treasury yield continues its rapid climb. The 10-year yield was up by 6 basis points to 1.54%, its hi...

The Immutep Ltd (ASX: IMM) share price is pushing higher again on Monday despite the market decline. At the time of writing, the biotechnology company’s shares are up almost 4% to 55 cents. This means the Immutep share price is now up 25%...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

ShareCafeThe Week that Was – August 30-September 3, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week The Healthcar...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Small-cap biotech stock Immutep [ASX:IMM] is on the up today. Shares are currently trading 7.92% higher at time of writing. Climbing higher thanks to some positive news in relation to the company’s ongoing clinical trials. The post 7% Gain...

Small-cap biotech stock Immutep Ltd [ASX:IMM] is on the up today. The IMM share price is currently trading 7.92% higher at time of writing... The post 7% Up For Immutep Share Price — Progresses Clinical Trials (ASX:IMM) appeared first on M...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is off its intraday lows but still trading lower. At the time of writing, the benchmark index is down 0.3% to 7,513.5 points. Four ASX shares that are not letting that hold them back...

The Immutep Ltd (ASX: IMM) share price is gaining today following news of the company’s Two ACTive Immunotherapies (TACTI-002) trial. Recruitment for the trial’s stage 2 of part B is now officially complete. Right now, the Immutep share pr...

ShareCafeImmutep Leading the development of immunotherapy for cancer and autoimmune diseases   Fund manager James McDonald at the Pengana High Conviction Equities Fund provides insight into some of the current opportunities arising for the...

Immutep (ASX:IMM) has announced that its Chinese partner for eftilagimod alpha (efti), EOC Pharma, is planning to expand its clinical trial pipeline for the investigative immunotherapy.

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

The ASX 200 closed at 7,488 points which was 0.04% down from yesterday but up 0.37% from last Friday. The ASX Emerging Companies Index lost 0.57% to close at 2,285 points. The best sector was industrials which gained 1.07%. Tech and consume...